Physician profile
Megan E Daly
NPI 1780863340
$31,813.89
in general payments reported to CMS, 2019-2025
13 companies · $10K in 2025
The $10K reported for 2025 was more than what 97% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2022: $6,461 · 2023: $478 · 2024: $14K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Honoraria: $2,800 · Food and Beverage: $1,260 · Travel and Lodging: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,647.50 |
| Honoraria | $2,800.00 |
| Food and Beverage | $1,259.57 |
| Travel and Lodging | $531.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22,022.28 | 2022-2025 | Tagrisso, Imfinzi, Enhertu |
| Novocure INC. | $3,657.44 | 2022-2025 | Optune |
| Astrazeneca Uk Limited | $3,185.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,104.75 | 2019-2024 | |
| Genentech USA, INC. | $235.42 | 2023 | Tecentriq, Alecensa |
| Zap Surgical Systems, INC. | $154.05 | 2023 | Zap-X Treatment Planning Software, Zap-X Mv Imager, Zap-X Treatment Delivery Software |
| Accuray Incorporated | $115.66 | 2024 | |
| Genentech, INC. | $113.69 | 2022 | |
| Gilead Sciences, INC. | $107.69 | 2024 | |
| Lilly USA, LLC | $88.91 | 2019 | |
| Mirati Therapeutics, INC. | $29.00 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.